Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (13860)	1/29/1998 11:08:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

No.

To: Hippieslayer who wrote (13860)	1/29/1998 11:24:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

FUGAZI, Jesse Eisinger posted a CORR story this morning at thestreet.com His article did suggest that the CORR decision was a negative for the entire sector. In fact he quoted one of the big boys who was long on CORR as saying that he would not invest in Biotechs again (and he might have also been the one who said that if a 11,000 patient trial wasn't good enough, then nothing was). I take a somewhat different view. If a trial requires 11,000 patients to acheive statistical significance, then the results have to be marginal at best. I'm not sure that investers (institutional as well as retail) have a solid grasp of this aspect.